Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.84 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.70 |
| ▸ | BRD2 | P25440 | 1/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.55 |
| ▸ | TSPO | P30536 | 1/20 | 0.55 |
| ▸ | EP300 | Q09472 | 1/20 | 0.55 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16047200 | 0.91 | BRD4 (1.00) | BRD4BRDTBRD2ADORA2BTSPO | |
| SCHEMBL16047800 | 0.84 | BRD4 (0.67) | BRD4BRDTBRD2BRD3 | |
| SCHEMBL16046073 | 0.83 | BRD4 (1.00) | BRD4BRDTBRD2ADORA2BTSPO | |
| SCHEMBL16048815 | 0.81 | BRD4 (0.65) | BRD4BRDT | |
| SCHEMBL16046548 | 0.80 | BRD4 (0.64) | BRD4BRDTBRD2ADORA2BTSPO | |
| SCHEMBL16047428 | 0.80 | BRD4 (0.79) | BRD4 | |
| SCHEMBL16045679 | 0.80 | BRD4 (0.69) | BRD4 | |
| SCHEMBL16044764 | 0.79 | BRD4 (0.66) | BRD4 | |
| SCHEMBL16045881 | 0.79 | BRD4 (0.66) | BRD4 | |
| SCHEMBL16044762 | 0.79 | BRD4 (0.66) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160237084-A1 | DIHYDRO-PYRROLOPYRIDINONE INHIBITORS | ABBVIE INC (US) | 2016-08-18 | — | — | US | claimed |
| US-9321764-B2 | Dihydro-pyrrolopyridinone inhibitors | ABBVIE INC. (US) | 2016-04-26 | — | — | US | claimed |
| CN-105164130-A | Dihydro-pyrrolopyridone bromodomain inhibitors | ABBVIE INC | 2015-12-16 | — | — | CN | claimed |
| US-20140275026-A1 | DIHYDRO-PYRROLOPYRIDINONE INHIBITORS | ABBVIE INC. | 2014-09-18 | — | — | US | claimed |
| US-20160237084-A1 | DIHYDRO-PYRROLOPYRIDINONE INHIBITORS | ABBVIE INC (US) | 2016-08-18 | — | — | US | disclosed |
| US-9321764-B2 | Dihydro-pyrrolopyridinone inhibitors | ABBVIE INC. (US) | 2016-04-26 | — | — | US | disclosed |
| EP-2970276-A1 | DIHYDRO-PYRROLOPYRIDINONE BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| CN-105164130-A | Dihydro-pyrrolopyridone bromodomain inhibitors | ABBVIE INC | 2015-12-16 | — | — | CN | disclosed |
| WO-2014165143-A1 | DIHYDRO-PYRROLOPYRIDINONE BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140275026-A1 | DIHYDRO-PYRROLOPYRIDINONE INHIBITORS | ABBVIE INC. | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237084-A1 | DIHYDRO-PYRROLOPYRIDINONE INHIBITORS | DPYD, QDPR, DHFR | BRD4 676/4885BRDT 1656/4885BRD2 2475/4885 |
| US-20140275026-A1 | DIHYDRO-PYRROLOPYRIDINONE INHIBITORS | DPYD, QDPR, DHFR | BRD4 676/4885BRDT 1656/4885BRD2 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.